title: Surrogate markers of efficacy for medical treatment of viral hepatitis.
abstract: As a chronic illness, hepatitis presents a challenge for clinical research, regulatory bodies, and clinicians treating patients - how can one adequately assess the effectiveness of antiviral therapy after years or decades of undiagnosed infection? Because the outcome of infection with hepatitis B or C (HBV, HCV) may follow years or decades of infection, the clinical benefit of a therapeutic may not be recognized during the short time frames of most human clinical trials. This is in clear contrast to many other therapeutics, where the outcome and efficacy can be evaluated in few weeks or months. In HBV and HCV, it is impractical to wait until the disease has abated to determine a drug's benefit, so surrogate markers that can predict disease outcome are essential to developing effective therapies. This review will highlight the ability of surrogate markers to detect early disease and to evaluate the effectiveness of HBV and HCV therapies.
authors: Director, Drexel Institute for Biotechnology and Virology Research Professor, Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia.
authors: Timothy M
authors: TM
authors: Block
authors: W Thomas
authors: WT
authors: London
keywords: HBV viremia; adefovir; hepatitis B; hepatitis C; hepatitis therapy; hepatocellular carcinoma; lamivudine; surrogate markers
references: J Mol Diagn. 2004 May;6(2):101-7
references: 15096565
references: Proteomics. 2004 Mar;4(3):826-38
references: 14997503
references: Microbiol Mol Biol Rev. 2000 Mar;64(1):51-68
references: 10704474
references: J Cancer Res Clin Oncol. 1997;123(8):435-40
references: 9292706
references: J Hepatol. 2000 Feb;32(2):300-6
references: 10707871
references: Cancer. 1988 Feb 15;61(4):769-74
references: 2448024
references: N Engl J Med. 1997 Jan 30;336(5):347-56
references: 9011789
references: J Hepatol. 2001 Apr;34(4):603-5
references: 11394662
references: J Hepatol. 1987 Apr;4(2):269-79
references: 3035005
references: Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):559-65
references: 9681522
references: J Gastroenterol. 2003;38(9):865-76
references: 14569444
references: Hepatology. 2002 Nov;36(5 Suppl 1):S145-51
references: 12407588
references: Hepatology. 2003 May;37(5):1114-21
references: 12717392
references: N Engl J Med. 1999 Mar 11;340(10):745-50
references: 10072408
references: J Viral Hepat. 1997 May;4(3):199-208
references: 9181529
references: Clin Chim Acta. 1984 Jun 13;139(3):313-6
references: 6204793
references: Mol Biol Cell. 2002 Jun;13(6):1929-39
references: 12058060
references: Ann Intern Med. 1988 Mar;108(3):390-401
references: 2449110
references: Hepatology. 2002 Nov;36(5 Suppl 1):S47-56
references: 12407576
references: Dis Markers. 2001;17(3):179-89
references: 11790885
references: J Gen Virol. 2000 Jul;81(Pt 7):1631-48
references: 10859368
references: Hepatology. 2003 Jun;37(6):1309-19
references: 12774009
references: Hepatology. 2000 Nov;32(5):1131-7
references: 11050066
references: Gastroenterology. 2001 Jun;120(7):1828-53
references: 11375963
references: J Med Virol. 2004 Jan;72(1):46-51
references: 14635010
references: Oncogene. 2003 Aug 11;22(33):5093-107
references: 12910247
references: Hepatology. 1998 Oct;28(4):1161-5
references: 9755258
references: Hepatology. 1995 Aug;22(2):432-8
references: 7543434
references: J Hepatol. 2003;38 Suppl 1:S90-103
references: 12591188
references: Hepatology. 2001 Dec;34(6):1225-41
references: 11732013
references: Proteomics. 2003 May;3(5):601-9
references: 12748940
references: J Med Virol. 2004 Jan;72(1):35-40
references: 14635008
references: Clin Chem. 2004 Jan;50(1):211-3
references: 14709652
references: Hepatology. 2002 Nov;36(5 Suppl 1):S35-46
references: 12407575
references: Cancer. 1998 May 1;82(9):1643-8
references: 9576283
references: Hepatology. 2003 Aug;38(2):518-26
references: 12883497
references: Clin Liver Dis. 2001 Feb;5(1):87-107, vi
references: 11218921